Despite repeated warnings from telehealth groups, Congress failed to extend the pandemic-era telehealth policies before they lapsed on Oct. 1. Now, providers are scrambling to manage the disruption to virtual care reimbursement and access.
Telehealth flexibilities expire amid government shutdown Read More »
At the heart of the agreement is Pfizer’s $70 billion commitment to U.S.-based manufacturing and an exemption from tariffs for three years. While the reaction was mostly positive from Wall Street, other observers noted that the benefits for patients are unclear at best.
Pfizer’s Drug Pricing Deal With Trump Raises Questions About Access Read More »
The medical device industry has a jam-packed year of events for professionals to attend, including the J.P. Morgan Healthcare Conference, DeviceTalks Boston and AdvaMed’s annual medtech meeting.
As with recent rejections for Biogen and Scholar Rock, manufacturing issues stymied a regulatory bid from Fortress Biotech and Sentynl Therapeutics. Fortress said the FDA did not flag problems with the drug’s safety or efficacy.
Fortress, Sentynl Fail To Secure FDA Nod in Rare Pediatric Disease Read More »
Novo Nordisk and Heartseed first partnered in 2021 to develop an investigational cell therapy for heart failure.
Novo Breaks $598M Heartseed Pact Amid ‘Decisive Restructuring’ by New CEO Read More »
The first oral BTK blocker for chronic spontaneous urticaria, Rhapsido offers a more convenient treatment option for patients who still show symptoms after antihistamine treatment.
Novartis Secures First FDA Approval of Oral BTK Inhibitor for Chronic Hives Read More »
The business separation, expected to be completed by the end of 2026, will result in two new companies, one focused on biopharma operations and the other on royalty management.
AnaptysBio Plans Business Split To Sharpen Focus on Asset Value Read More »
These are the events healthcare leaders should plan for next year, covering topics like digital health, rural care and financial management.
M&A headlined for a second straight week as Genmab acquired Merus for $8 billion; Pfizer strikes most-favored-nation deal with White House; CDER Director George Tidmarsh caused a stir with a now-deleted LinkedIn post; GSK CEO Emma Walmsley will step down from her role; and uniQure’s gene therapy offers new hope for patients with Huntington’s disease.
M&A Picks Up, Walmsley Moves On, Pfizer’s MFN Deal and Hope for Huntington’s Read More »
Unos científicos han aprovechado la física cuántica para detectar la presencia de biomoléculas sin necesidad de una fuente de luz externa, superando de este modo una de las mayores trabas a la hora de usar biosensores ópticos en medicina y vigilancia medioambiental …
